Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Nexstim Plc Issuance of shares and warrants pursuant to the financing arrangement announced on 21 July 2016

Nexstim Oyj
Posted on: 22 Aug 16


Company announcement, Helsinki, 22 August 2016, at 18:00 pm

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or the " Company "), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces that, pursuant to the authorisations received from the Company's Extraordinary General Meeting on 18 August 2016 and the financing arrangement entered into with Bracknor Investment and the Finnish Innovation Fund Sitra (" Sitra ") which was announced on 21 July 2016, the Board of Directors of the Company has today resolved on:

  • issuing 719,007 new shares to Sitra with a subscription price of EUR 500,000 in total and issuing 251,652 warrants to Sitra entitling to subscribe for shares in the Company in accordance with the terms and conditions of the warrants;
  • issuing 795,431 new shares to the Company itself without payment; and
  • listing the new shares issued pursuant to the above resolutions.

Martin Jamieson, CEO

Further information is available on the website or by contacting:

Nexstim                                                                                                           +447715163942
Martin Jamieson, Chief Executive Officer                        
UB Securities Oy (Certified Adviser)                                                          +358 (0)9 2538 0246

Consilium Strategic Communications                                                        +44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Laura Thornton           

About Nexstim Plc
Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) system for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE-marked for chronic neuropathic pain, major depression and stroke therapy. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit


Nexstim Plc

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Nexstim Oyj via GlobeNewswire

Last updated on: 23/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.